ImmunityBio – 2026-01-23 - increase Confidence 8/10

IBRX – increase in Days/Weeks

ImmunityBio reported a 700% year-over-year surge in 2025 net product revenue to $113M, driven by ANKTIVA sales, coinciding with the FDA clearing a path for sBLA resubmission without requiring new clinical trials.

Why This Matters

The combination of explosive revenue growth and a de-risked regulatory pathway significantly improves commercial visibility for ANKTIVA in a large urothelial cancer market, making near-term approval and revenue acceleration highly probable—this is precisely the catalyst the market has been pricing in, especially with stock already up over 100% YTD.

Key Insights

• Revenue Growth: Preliminary 2025 net product revenue of $113M (+700% YoY), Q4 alone reached $38.3M (+20% QoQ)
• News Impact: FDA provides clear sBLA resubmission path for ANKTIVA in BCG-unresponsive NMIBC with papillary tumors—no new trials required → near-term approval likely
• Risk/Offset: Negative free cash flow (-$398M TTM) and negative equity highlight ongoing dilution risk, but cash burn is being offset by revenue ramp

Practical Implications

• Bull Case: FDA approval anticipation and expanding ANKTIVA adoption → stock re-rates toward $7.00–$8.00, testing 52-week high
• Bear Case: Delay in sBLA approval or slower-than-expected international rollout could trigger pullback toward $5.50 support
• Confidence: 8/10 – Strong clinical data, clear regulatory path, and accelerating revenue validate growth trajectory

Prediction: increase

Reference:

• https://blockonomi.com/immunitybio-ibrx-stock-jumps-20-as-fda-clears-path-for-bladder-cancer-treatment/
• https://tokenist.com/why-is-immunitybio-ibrx-stock-up-premarket-anktiva-sales-jump-700/
• https://stockstotrade.com/immunitybioinc-ibrx-news-2025_11_29-2/